Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill caps the U.S. retail list price for covered prescription drugs and biological products so it may not exceed the average retail list price among Canada, France, Germany, Italy, Japan, and the United Kingdom. Manufacturers must annually report list prices in the U.S. and those six countries; the HHS Secretary will calculate the international average and issue implementing regulations.
Support vs opposition to direct price caps and government control
Relative to its intended legislative type, this bill establishes a clear substantive rule (a cap on U.S. retail list prices tied to an average of six foreign markets) and assigns HHS administrative duties and a civil-penalty enforcement mechanism, but it leaves many implementation-critical details unspecified.
The bill caps the U.S. retail list price for covered prescription drugs and biological products so it may not exceed the average retail list price among Canada, France, Germany, Italy, Japan, and the United Kingdom.
Manufacturers must annually report list prices in the U.S. and those six countries; the HHS Secretary will calculate the international average and issue implementing regulations.
Manufacturers who sell above the cap are subject to a civil monetary penalty equal to (U.S. list price minus the international average) multiplied by 10, assessed per unit sold.
Targeted but high‑impact, lacks compromise, faces powerful stakeholder resistance and foreseeable legal/implementation challenges; low probability as introduced.
Relative to its intended legislative type, this bill establishes a clear substantive rule (a cap on U.S. retail list prices tied to an average of six foreign markets) and assigns HHS administrative duties and a civil-penalty enforcement mechanism, but it leaves many implementation-critical details unspecified.
Support vs opposition to direct price caps and government control
These are examples from the analysis, not a ranked list of the most-affected groups.
Support vs opposition to direct price caps and government control
Likely broadly supportive because the bill directly aims to lower U.S. drug prices and increase price alignment with other wealthy countries.
Will welcome mandatory reporting and enforcement tools, but note possible loopholes and legal challenges.
May press for clarity on protecting patient access and ensuring penalties don't create unintended harms.
Cautiously favorable to the goal of lowering prices but concerned about implementation, measurement, and economic side effects.
Will seek phased implementation, clear methodology, and exemptions or adjustments for rare circumstances.
Wants fiscal and market impact analyses and regulatory clarity.
Likely opposed as an intrusive government price control that interferes with market pricing and innovation incentives.
Will highlight risks to R&D, job impacts, and regulatory overreach.
Prefers market-based reforms or international importation instead.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted but high‑impact, lacks compromise, faces powerful stakeholder resistance and foreseeable legal/implementation challenges; low probability as introduced.
The bill has not accumulated any surfaced votes yet.
Support vs opposition to direct price caps and government control
Targeted but high‑impact, lacks compromise, faces powerful stakeholder resistance and foreseeable legal/implementation challenges; low prob…
Relative to its intended legislative type, this bill establishes a clear substantive rule (a cap on U.S. retail list prices tied to an average of six foreign markets) and assigns HHS administrative duties and a civil-pe…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.